Search Results - "Fallatah, Maryam M."
-
1
Discovery of compounds that reactivate p53 mutants in vitro and in vivo
Published in Cell chemical biology (15-09-2022)“…The tumor suppressor p53 is the most frequently mutated protein in human cancer. The majority of these mutations are missense mutations in the DNA binding…”
Get more information
Journal Article -
2
Pyrimidine Triones as Potential Activators of p53 Mutants
Published in Biomolecules (Basel, Switzerland) (08-08-2024)“…p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in…”
Get full text
Journal Article -
3
Small-molecule correctors and stabilizers to target p53
Published in Trends in pharmacological sciences (Regular ed.) (01-05-2023)“…The tumor suppressor p53 is among the most attractive precision oncology targets. The two main small-molecule-based approaches for targeting p53 are blocking…”
Get full text
Journal Article -
4
Enantiomer of the novel flexible heteroarotinoid, SL-1-09, blocks cell cycle progression in breast cancer cells
Published in European journal of pharmacology (05-11-2019)“…Flexible heteroarotinoids (Flex-Hets) are compounds with promising anti-cancer activities. SHetA2, a first-generation Flex-Het, has been shown to inhibit the…”
Get full text
Journal Article -
5
Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth
Published in Cancer letters (01-11-2017)“…SL-1-18 (1-(chrysen-6-yl)-3-(4-nitrophenyl)thiourea) is new flexible heteroarotinoid (Flex-Het) analog derived from the parent compound, SHetA2, and our…”
Get full text
Journal Article -
6
Abstract 113: Evaluating the anticancer activity of two flexible heteroarotinoid analogs on breast cancer
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Abstract Flexible heteroarotiniods (flex-hets) are compounds derived from retinoic acid and recent studies have indicated that these compounds exhibit…”
Get full text
Journal Article